Vasoactive Intestinal Peptide (VIP) in CIRS Contexts

internal_protocolexpert_opinion · status: needs_provider_review

Details

Author: Axiom Knowledge Base

Citation: Internal reference summary compiled for the Axiom knowledge base (2026).

Summary (generated — provider review required)

Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide with broad regulatory roles in immune modulation, vasodilation, and neuroendocrine signaling. In the chronic inflammatory response syndrome (CIRS) / mold-illness literature associated with Shoemaker protocols, intranasal VIP is discussed as a later-stage intervention after other corrective steps. Mechanism.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (4) · phenotypes (1)

evidence_reference, mechanism, safety_reference, dosing_reference

Phenotypes: dysautonomia

Findings (6) · awaiting review (4)

dosing · pending

This is expert-opinion-level background organized for provider review, not a treatment recommendation or dosing guidance.

regulatory · pending

Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide with broad regulatory roles in immune modulation, vasodilation, and neuroendocrine signaling.

mechanism · pending

Mechanism.

mechanism · pending

VIP acts on VPAC receptors and has anti-inflammatory and immunoregulatory effects, including modulation of T-cell responses and downregulation of pro-inflammatory cytokines.

regulatory · pending

Proponents describe normalization of regulatory markers and symptom improvement in selected CIRS patients.

safety · pending

Safety considerations.

Processing

Processed into 1 searchable section.